Neuroprotective effects of the monoamine oxidase inhibitor Tranylcypromine and its amide derivatives against Abeta(1-42)-induced toxicity(805 views) Caraci F, Pappalardo G, Basile L, Giuffrida A, Copani A, Tosto R, Sinopoli A, Giuffrida ML, Pirrone E, Drago F, Pignatello R, Guccione S
Keywords: Amyloid, Anti-Aggregant Acstivity, Antidepressants, Butyric Acid (pubchem Cid: 264), Neurons, Neuroprotection, Tranylcypromine (pubchem Cid: 19493 Or 26070), Tranylcypromine Acetamide (pubchem Cid: 583384), Anti-Aggregant Activity, Amyloid Beta Protein[1-42], Glial Fibrillary Acidic Protein, Microtubule Associated Protein 2, Tranylcypromine Butyramide, Tranylcypromine Derivative, Unclassified Drug, Alzheimer Disease, Animal Cell, Animal Experiment, Animal Model, Article, Controlled Study, Drug Degradation, Drug Efficacy, Drug Potency, Drug Stability, Drug Synthesis, In Vitro Study, Nerve Cell Necrosis, Nerve Degeneration, Neurotoxicity, Nonhuman, Priority Journal, Protein Aggregation,
Affiliations: *** IBB - CNR ***
Department of drug Sciences, university of Catania, Catania, Italy; IRCCS Associazione Oasi maria S.S., institute for research on mental Retardation and brain aging, Troina, Italy. Electronic address: Carafil@hotmail.com., National research council, institute of Biostructures and Bioimaging, Catania, Italy., Department of drug Sciences, university of Catania, Catania, Italy., Department of drug Sciences, university of Catania, Catania, Italy; National research council, institute of Biostructures and Bioimaging, Catania, Italy., National research council, institute of Biostructures and Bioimaging, Catania, Italy; PhD Program in Translational Biomedicine, university of Catania., Department of biomedical and Biotechnological Sciences, university of Catania, Catania, Italy.,
References: Al-Nuaimi, S.K., Mackenzie, E.M., Baker, G.B., Monoamine oxidase inhibitors and neuroprotection: a review (2012) Am. J. Ther., 19, pp. 436-44
Baker, G.B., Sowa, B., Todd, K.G., Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? (2007) J. Psychiatry Neurosci., 32, pp. 313-315
Ballard, C., Day, S., Sharp, S., Wing, G., Sorensen, S., Neuropsychiatric symptoms in dementia: importance and treatment considerations (2008) Int. Rev. Psychiatry, 20, pp. 396-404
Bar-Am, O., Amit, T., Weinreb, O., Youdim, M.B., Mandel, S., Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation (2010) J. Alzheimers Dis., 21, pp. 361-371
Basile, L., Pappalardo, M., Guccione, S., Milardi, D., Ramsay, R.R., Computational comparison of imidazoline association with the I2 binding site in human monoamine oxidases (2014) J. Chem. Inf. Model., 54, pp. 1200-1207
Baskaran, A., Carvalho, A.F., Mansut, R.B., McIntyre, R.S., Are major depressive disorder and diabetes mellitus amyloidogenic conditions? (2014) CNS Neurol. Disord. Drug Targets, 13, pp. 1667-1676
Binda, C., Milczek, E.M., Bonivento, D., Wang, J., Mattevi, A., Edmondson, D.E., Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies (2011) Curr. Top. Med. Chem., 11, pp. 2788-2796
Blackley, H.K., Patel, N., Davies, M.C., Roberts, C.J., Tendler, S.J., Wilkinson, M.J., Williams, P.M., Morphological development of beta(1-40) amyloid fibrils (1999) Exp. Neurol., 158, pp. 437-443
Cai, Z., Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (2014) Mol. Med. Rep., 9, pp. 1533-1541
Caraci, F., Copani, A., Nicoletti, F., Drago, F., Depression and Alzheimer's disease: neurobiological links and common pharmacological targets (2010) Eur. J. Pharmacol., 626, pp. 64-71
Caraci, F., Molinaro, G., Battaglia, G., Giuffrida, M.L., Riozzi, B., Traficante, A., Bruno, V., Nicoletti, F., Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective (2011) Mol. Pharmacol., 79, pp. 618-626
Caraci, F., Castellano, S., Salomone, S., Drago, F., Bosco, P., Di Nuovo, S., Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers? (2014) CNS Neurol. Disord. Drug Targets, 13, pp. 173-186
Carradori, S., Petzer, J.P., Novel monoamine oxidase inhibitors: a patent review (2012-2014) (2015) Expert Opin. Ther. Pat., 25, pp. 91-110
Carradori, S., Silvestri, S., New frontiers in selective human MAO-B inhibitors (2015) J. Med. Chem.
Chung, J.K., Plitman, E., Nakajima, S., Chow, T.W., Chakravarty, M.M., Carravagio, F., Gerretsen, P., Graff-Guerrero, A., Lifetime history of depression predicts increased amyloid-β accumulation in patients with mild cognitive impairment (2015) J. Alzheimers Dis., 45, pp. 907-919
Copani, A., Condorelli, F., Caruso, A., Vancheri, C., Sala, A., Giuffrida Stella, A.M., Canonico, P.L., Sortino, M.A., Mitotic signaling by beta amyloid causes neuronal death (1999) FASEB J., 13, pp. 2225-2234
De Bona, P., Giuffrida, M.L., Caraci, F., Copani, A., Pignataro, B., Attanasio, F., Cataldo, S., Rizzarelli, E., Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Abeta(1-42) fibrillogenesis and toxicity (2009) J. Pept. Sci., 15, pp. 220-228
Desino, K.E., Pignatello, R., Guccione, S., Basile, L., Ansar, S., Michaelis, M.L., Ramsay, R.R., Audus, K.L., TCP-But: a derivative of TCP showing improved blood-brain permeability (2009) Biochem. Pharmacol., 78, pp. 1412-1417
Eleuteri, S., Di Giovanni, S., Rockenstein, E., Mante, M., Adame, A., Trejo, M., Wrasidlo, W., Lashuel, H.A., Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease (2015) Neurobiol. Dis., 74, pp. 144-157
Emilsson, L., Saetre, P., Balciuniene, J., Castensson, A., Cairns, N., Jazin, E.E., Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients (2002) Neurosci. Lett., 326, pp. 56-60
Giacobini, E., Gold, G., Alzheimer disease therapy - moving from amyloid-β to tau (2013) Nat. Rev. Neurol., 9, pp. 677-686
Gong, Y., Klein, W.L., Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 10417-10422
Hardy, J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal (2009) J. Neurochem., 110 (4), pp. 1129-1134
Jan, A., Adolfsson, O., Allaman, I., Buccarello, A.L., Magistretti, P.J., Pfeifer, A., Muhs, A., Lashuel, H.A., Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species (2010) J. Biol. Chem., 286, pp. 8585-8596
Kennedy, B.P., Ziegler, M.G., Alford, M., Hansen, L.A., Thal, L.J., Masliah, E., Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease (2003) J. Neural. Transm., 110, pp. 789-801
Kessing, L.V., Søndergård, L., Forman, J.L., Andersen, P.K., Antidepressants and dementia (2009) J. Affect. Disord., 117, pp. 24-29
Klein, W.L., Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? (2013) J. Alzheimers Dis., 33 (S1), pp. S49-S65
Loo, D.T., Copani, A., Pike, C.J., Whittemore, E.R., Walencewicz, A.J., Cotman, C.W., Apoptosis is induced by beta-amyloid in cultured central nervous system neurons (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 7951-7955
Nibuya, M., Morinobu, S., Duman, R.S., Regulation of BDNF and trkB mRNA in rat brain by chonic electroconvulsive seizure and antidepressant drug treatments (1995) J. Neurosci., 15, pp. 7539-7547
Nibuya, M., Nestler, E.J., Duman, R.S., Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus (1996) J. Neurosci., 16, pp. 2365-2372
Ownby, R.L., Crocco, E., Acevedo, A., Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis (2006) Arch. Gen. Psychiatry, 63, pp. 530-538
Pennington, P.R., Wei, Z., Rui, L., Doig, J.A., Graham, B., Kuski, K., Gabriel, G.G., Mousseau, D.D., Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase - a activity in vitro (2011) J. Neural Transm., 118, pp. 987-995
Pignatello, R., Puleo, A., Guccione, S., Raciti, G., Acquaviva, R., Campisi, A., Ventura, C.A., Puglisi, G., Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. I. Synthesis and biological evaluation of lipophilic conjugates of tranylcypromine (2005) Eur. J. Med. Chem., 40, pp. 1074-1079
Reitz, C., Brayne, C., Mayeux, R., Epidemiology of Alzheimer disease (2011) Nat. Rev. Neurol., 7, pp. 137-152
Shulman, K.I., Herrmann, N., Walker, S.E., Current place of monoamine oxidase inhibitors in the treatment of depression (2013) CNS Drugs, 27, pp. 789-797
Song, M.S., Matveychuk, D., MacKenzie, E.M., Duchcherer, M., Mousseau, D.D., Baker, G.B., An update on amine oxidase inhibitors: multifaceted drugs (2013) Prog. Neuropsychopharmacol. Biol. Psychiatry, 44, pp. 118-124
Walsh, D.M., Selkoe, D.J., A beta oligomers - a decade of discovery (2007) J. Neurochem., 101, pp. 1172-1184
Wei, Z., Gabriel, G.G., Rui, L., Cao, X., Pennington, P.R., Chlan-Fourney, J., Nazarali, A.J., Mousseau, D.D., Monoamine oxidase - a physically interacts with presenilin-1(M146V) in the mouse cortex (2012) J. Alzheimers Dis., 28, pp. 403-422
Yáñez, M., Viña, D., Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease (2013) Curr. Top. Med. Chem., 13, pp. 1692-1706
Neuroprotective effects of the monoamine oxidase inhibitor Tranylcypromine and its amide derivatives against Abeta(1-42)-induced toxicity